Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

induction

induction is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 34
News articles 0
Drug details — induction
Class
—
Route
—
Patents
20
Programs
34
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

induction is an FDA-listed pharmaceutical active ingredient.

Key facts

INN induction

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 2 cycles induction chemotherapy Phase 3 · First People's Hospital · Locally Advanced Nasopharyngeal Carcinoma
  2. 2215-CL-0201 Phase 3 · Astellas Pharma · Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in
  3. APHP240909 Phase 3 · PARItec · Patient with stabilized SSc-ILD (as defined by a decline of
  4. HM16/047 Phase 3 · Takeda · Multiple Myeloma
  5. Induction Chemotherapy Phase 3 · First People's Hospital · Locally Advanced Nasopharyngeal Carcinoma
  6. JPB898 (Induction and Maintenance) Phase 3 · Sandoz (Japan) · Melanoma
  7. MyelomaXIV Phase 3 · Takeda · Multiple Myeloma
  8. PF-06651600 Induction Dose Phase 3 · Pfizer · Alopecia Areata

Related patents

Browse patents

  1. WO 2025169901

    CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE PRÉSENTANT UNE ACTIVITÉ D'INDUCTION DE LA DÉCOMPOSITION DE PROTÉINES MUTANTES KRAS

    Expires Wed Aug 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12310986

    Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2025058008

    CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE AYANT POUR ACTIVITÉ L'INDUCTION DE LA DÉCOMPOSITION DE LA PROTÉINE KRAS MUTANTE G12D

    Expires Wed Mar 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11873319

    Cyclic di-nucleotide induction of type I interferon

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11781110

    Induction of corneal endothelial cells

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11083801

    Factor VIII mutation repair and tolerance induction

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11065330

    Induction of antigen-specific tolerance by peripheral phagocytosis

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10980841

    Methods and compositions for in vivo induction of pancreatic beta cell formation

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10293002

    Methods and compositions for in vivo induction of pancreatic beta cell formation

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10272163

    Factor VIII mutation repair and tolerance induction

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10155014

    Cyclic di-AMP induction of type I interferon

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9763987

    Cyclic di-AMP induction of type I interferon

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9649344

    Methods and compositions for in vivo induction of pancreatic beta cell formation

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9562070

    Induction of tumor immunity by variants of folate binding protein

    Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9526777

    Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9457052

    Allograft tolerance induction

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9193739

    Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9061048

    Cyclic di-AMP induction of type I interferon

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8492347

    Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus

    Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8440202

    Induction of an immune response against dengue virus using the prime-boost approach

    Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is induction?

induction is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.